Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Over $400k annually for…

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Sep 21, 2021 9:37am

94 Views

Post# 33891608

RE:Over $400k annually for…

Another ADC is good news, especially as the BLA was filed in Feb, Accellerated App granted in April, and now approved in Sep. All on phase 2 with 101 patients and an objective response of only 24% and durability of response of 8 months in cervical cancer, but with a high percentage of safety issues many of which are on the serious side (50% for hemoglobin and lymphocyte decrease and 40% peripheral neuropathy) .

So the ADC not internalizing a lot of the chemo clearly leads to issues with dosage, duration and treatment window. More numbers and a timeline to keep in mind. On that timeline, you could see TH1902 move pretty fast based on positive results.

scarlet1967 wrote:

“Tivdak’s wholesale acquisition cost is $5,885 per 40mg single dose vial, with patients’ individual costs determined by body weight and duration of therapy, a spokesperson said by email. The companies estimate an average WAC per patient per month of $34,000, before discounts or rebates.”

This ADC approved yesterday will gross estimated over $400k annually.

Seagen - Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer